Novel Nonchemo Combo (Len-R) Effective in Follicular Lymphoma Novel Nonchemo Combo (Len-R) Effective in Follicular Lymphoma
A novel chemotherapy-free regimen containing lenalidomide and rituximab showed similar efficacy but less toxicity than the standard combination of rituximab and chemotherapy in the RELEVANCE trial.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 20, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Survival Longer With Obinutuzumab Compared to Rituximab in CLL Survival Longer With Obinutuzumab Compared to Rituximab in CLL
New longer-term results with overall survival data confirm the superiority of the newer agent over the earlier-generation anti-CD20 drug rituximab for previously untreated chronic lymphocytic leukemia (CLL).Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 20, 2018 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Venetoclax/Rituximab Combo Approved for CLL/SLL
FDA warns, however, about the possibility of TLS due to rapid tumor cell destruction. (Source: CancerNetwork)
Source: CancerNetwork - June 19, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news

In DLBCL, Polatuzumab Combo Yields ‘Marked Improvement’ in CR, PFS, OS
Polatuzumab vedotin administered with bendamustine and rituximab significantly improved PET-based CR rates, PFS, and OS in DLBCL but not FL. (Source: CancerNetwork)
Source: CancerNetwork - June 15, 2018 Category: Cancer & Oncology Authors: John Schieszer Source Type: news

Rituximab Therapy in Lupus
No abstract available (Source: Lippincott's Bone and Joint Newsletter)
Source: Lippincott's Bone and Joint Newsletter - June 15, 2018 Category: Orthopaedics Tags: Perspective Source Type: news

AbbVie Announces New Undetectable Minimal Residual Disease Data from Phase 3 Relapsed/Refractory Chronic Lymphocytic Leukemia MURANO Trial of Venetoclax in Combination with Rituximab at 23rd European Hematology Association Annual Congress
83 percent (n=100) of 121 patients who achieved undetectable minimal residual disease (uMRD) at the end of combination therapy with VenR (n=194), maintained uMRD and were progression-free at 13.8 months of follow-up[1] uMRD response rates were consisten... Biopharmaceuticals, Oncology AbbVie, MURANO trial, venetoclax, chronic lymphocytic leukemia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 15, 2018 Category: Pharmaceuticals Source Type: news

New long-term data confirm Roche ’s Gazyva/Gazyvaro extends the lives of people with chronic lymphocytic leukaemia compared to MabThera/Rituxan
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced data from the final analysis of the CLL11 study evaluating Gazyva®/Gazyvaro® (obinutuzumab)-based treatment in previously untreated chronic lymphocytic leukaemia (CLL) which will be presented during the Presidential Symposium at the 23rd European Hematology Association (EHA) Annual Congress, 14 - 17 June, in Stockholm. (Source: World Pharma News)
Source: World Pharma News - June 15, 2018 Category: Pharmaceuticals Tags: Featured Roche Business and Industry Source Type: news

New long-term data confirm Roche ’s Gazyva/Gazyvaro extends the lives of people with chronic lymphocytic leukaemia compared to MabThera/Rituxan
Roche today announced data from the final analysis of the CLL11 study evaluating Gazyva ®/Gazyvaro® (obinutuzumab)-based treatment in previously untreated chronic lymphocytic leukaemia (CLL) which will be presented during the Presidential Symposium at the 23rd European Hematology Association (EHA) Annual Congress, 14 - 17 June, in Stockholm. (Source: Roche Media News)
Source: Roche Media News - June 15, 2018 Category: Pharmaceuticals Source Type: news

New long-term data confirm Roche ’s Gazyva/Gazyvaro extends the lives of people with chronic lymphocytic leukaemia compared to MabThera/Rituxan
Roche today announced data from the final analysis of the CLL11 study evaluating Gazyva ®/Gazyvaro® (obinutuzumab)-based treatment in previously untreated chronic lymphocytic leukaemia (CLL) which will be presented during the Presidential Symposium at the 23rd European Hematology Association (EHA) Annual Congress, 14 - 17 June, in Stockholm. (Source: Roche Investor Update)
Source: Roche Investor Update - June 15, 2018 Category: Pharmaceuticals Source Type: news

Roche announces FDA approval for Venclexta plus Rituxan for people with previously treated chronic lymphocytic leukaemia
Roche, announced today that the United States Food and Drug Administration (FDA) has approved Venclexta ® (venetoclax) in combination with Rituxan® (rituximab) for the treatment of people with chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least one prior therapy. (Source: Roche Media News)
Source: Roche Media News - June 11, 2018 Category: Pharmaceuticals Source Type: news

Roche announces FDA approval for Venclexta plus Rituxan for people with previously treated chronic lymphocytic leukaemia
Roche, announced today that the United States Food and Drug Administration (FDA) has approved Venclexta ® (venetoclax) in combination with Rituxan® (rituximab) for the treatment of people with chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least one prior therapy. (Source: Roche Investor Update)
Source: Roche Investor Update - June 11, 2018 Category: Pharmaceuticals Source Type: news

FDA approves Roche ’s MabThera/Rituxan (rituximab) for pemphigus vulgaris
Roche announced today that the US Food and Drug Administration (FDA) has approved MabThera/Rituxan ® (rituximab) for the treatment of adults with moderate to severe pemphigus vulgaris (PV), a rare, serious, potentially life-threatening condition characterised by progressive painful blistering of the skin and mucous membranes. (Source: Roche Investor Update)
Source: Roche Investor Update - June 8, 2018 Category: Pharmaceuticals Source Type: news

Deadly Skin Disorder Gets First New Drug in 60 Years
(MedPage Today) -- FDA approves rituximab (Rituxan) for pemphigus vulgaris (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - June 8, 2018 Category: Dermatology Source Type: news

Genentech Announces FDA Approval for Venclexta Plus Rituxan for People With Previously Treated Chronic Lymphocytic Leukemia
South San Francisco, CA -- June 8, 2018 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved Venclexta (venetoclax) in combination with Rituxan ... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - June 8, 2018 Category: Drugs & Pharmacology Source Type: news

FDA Approves Genentech ’s Rituxan (rituximab) for Pemphigus Vulgaris
South San Francisco, CA -- June 7, 2018 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved Rituxan (rituximab) for the treatment of adults with... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - June 7, 2018 Category: Drugs & Pharmacology Source Type: news

Combo Improves Outcomes in Waldenstrom's Macroglobulinema Combo Improves Outcomes in Waldenstrom's Macroglobulinema
The combination of ibrutinib plus rituximab dramatically extends progression-free survival over rituximab alone, regardless of treatment or mutational status.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 7, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Ibrutinib/Rituximab Yields Prolonged PFS in Waldenstr öm Macroglobulinemia
Bryant FurlowJun 4, 2018In the randomized phase III iNNOVATE trial, adding ibrutinib to rituximab significantly improved PFS in patients with Waldenstr öm macroglobulinemia. (Source: CancerNetwork)
Source: CancerNetwork - June 4, 2018 Category: Cancer & Oncology Authors: A Source Type: news

IMBRUVICA ® (ibrutinib) in Combination with Rituximab Showed Greater Efficacy Compared to Placebo Plus Rituximab in Patients with Waldenström’s Macroglobulinemia, a Rare and Incurable Form of Non-Hodgkin’s Lymphoma
(Source: Johnson and Johnson)
Source: Johnson and Johnson - June 2, 2018 Category: Pharmaceuticals Source Type: news

Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016
This research has led to a Practice Changing Update on DynaMed Plus. Itarticle concludes that CHOP plus 131 I tositumomab and CHOP plus rituximab may have similar 5- and 10-year overall survival, but CHOP plus rituximab may improve 10-year progression-free survival in adults with advanced follicular lymphoma. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - May 16, 2018 Category: Consumer Health News Source Type: news

Quiz: Genetics and Epidemiology of Diffuse Large B-Cell Lymphoma
Can you name biomarkers that are associated with PCNS-DLBCL? Are you aware of contraindications for use of rituximab in DLBCL? Test your knowledge by taking this multiquestion quiz. (Source: CancerNetwork)
Source: CancerNetwork - May 15, 2018 Category: Cancer & Oncology Authors: Bryant Furlow Tags: Hematologic Malignancies Quiz Source Type: news

Treatment of Chronic Antibody Mediated Rejection Treatment of Chronic Antibody Mediated Rejection
Is IVIG combined with rituximab a safe and effective treatment option for chronic antibody mediated rejection?American Journal of Transplantation (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 9, 2018 Category: Consumer Health News Tags: Transplantation Journal Article Source Type: news

Roche wins reprieve as Novartis biosimilar delayed in U.S.
LONDON/ZURICH (Reuters) - Roche has won a reprieve an expected deluge of cheaper versions of its biotech cancer drugs as U.S. regulators knocked back a biosimilar form of rituximab from Swiss rival Novartis. (Source: Reuters: Health)
Source: Reuters: Health - May 3, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Novartis biosimilar cancer drug hits U.S. regulatory bump
ZURICH (Reuters) - Novartis AG said its biosimilar version of rituximab to treat blood cancers and immunological diseases such as rheumatoid arthritis had not won regulatory approval from the U.S. Food and Drug Administration (FDA). (Source: Reuters: Health)
Source: Reuters: Health - May 3, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Doses of Rituximab for Retreatment in Rheumatoid Arthritis Doses of Rituximab for Retreatment in Rheumatoid Arthritis
How do standard and reduced dosing of rituximab compare in terms of maintenance and the risk for developing serious infections?Rheumatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 25, 2018 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news

Venetoclax/Rituximab Found Superior to Chemotherapy in CLL
The combination of rituximab and the BCL2 inhibitor venetoclax significantly lengthened PFS among CLL patients in the phase III MURANO trial. (Source: CancerNetwork)
Source: CancerNetwork - April 19, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Chronic Lymphocytic Leukemia Hematologic Malignancies News Source Type: news

Treatment for male anti-NMDA receptor encephalitis patients
(Bentham Science Publishers) Treatments for the anti-NMDA receptor encephalitis usually include steroids, intravenous immunoglobulin, plasma exchange, plasmapheresis, rituximab, cyclophosphamide and tumor resection. The researchers aimed to compare the efficacy of the treatments including intravenous immunoglobulin, plasma exchange, plasmapheresis, rituximab or cyclophosphamide for male anti-NMDA receptor encephalitis patients without tumor and to discuss potential biomarkers for this disease. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 14, 2018 Category: Cancer & Oncology Source Type: news

A Role for Rituximab in Lupus?
(MedPage Today) -- Half of refractory patients responded in 6 months (Source: MedPage Today Rheumatology)
Source: MedPage Today Rheumatology - March 8, 2018 Category: Rheumatology Source Type: news

A diagnosis you can ’t afford to miss
4 out of 5 stars Antibody-Mediated Encephalitis. Dalmau J, Graus F. N Engl J Med 2018 Mar 1;378:840-851. Reference TPR has posted before about anti-NMDA receptor encephalitis, a must-know, can’t-miss, humbling diagnosis that is distressingly easy to overlook. Although it is not a toxicologic condition, all toxicologists and emergency physicians should be thoroughly familiar with its presentation and clinical course. Let me explain why. NMDAR encephalitis often begins with behavioral changes, mood swings, and memory deficits in relatively young patients. According to this somewhat technical but excellent review, ...
Source: The Poison Review - March 2, 2018 Category: Toxicology Authors: Leon Gussow Tags: Medical anbitody-mediated encephalitis anti-NMDA receptor encephalitis brain on fire diagnosis Source Type: news

CLL Responds to Induction With RCC Regimen Plus Rituximab Maintenance
CLL patients responded well to induction with the RCC regimen cladribine, cyclophosphamide, and rituximab followed by maintenance rituximab. (Source: CancerNetwork)
Source: CancerNetwork - February 27, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Chronic Lymphocytic Leukemia Immuno Oncology Source Type: news

CD19 Antibody Targeting With MOR208 Is Active in DLBCL
Single-agent MOR208 showed promising activity with long-lasting responses in aggressive and indolent NHL subtypes, including in rituximab-refractory disease. (Source: CancerNetwork)
Source: CancerNetwork - February 22, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Diffuse Large B-Cell Lymphoma Follicular Lymphoma Source Type: news

Rituximab: More Effective Than Other Initial MS Treatments? Rituximab: More Effective Than Other Initial MS Treatments?
A Swedish database analysis shows that rituximab excels in newly diagnosed relapsing-remitting multiple sclerosis. Dr Laurie Barclay takes a closer look.Medscape Neurology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 14, 2018 Category: Consumer Health News Tags: Neurology & Neurosurgery Viewpoint Source Type: news

FDA grants priority review for Roche ’s MabThera/ Rituxan (rituximab) for pemphigus vulgaris
Roche announced today that the US Food and Drug Administration (FDA) has accepted the company ’s Supplemental Biologics License Application (sBLA) and granted Priority Review for the use of MabThera/Rituxan® (Rituximab) for the treatment of pemphigus vulgaris (PV), a rare, life-threatening condition characterized by progressive painful blistering of the skin and mucous membranes. (Source: Roche Investor Update)
Source: Roche Investor Update - February 14, 2018 Category: Pharmaceuticals Source Type: news

Rituxan Hycela (Rituximab And Hyaluronidase Human Injection) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - January 31, 2018 Category: Drugs & Pharmacology Source Type: news

Continued Excellent Outcomes in Previously Untreated Patients With Follicular Lymphoma After Treatment With CHOP Plus Rituximab or CHOP Plus 131I-Tositumomab: Long-Term Follow-Up of Phase III Randomized Study SWOG-S0016
This research article reports patients in the CHOP- tositumomab arm had significantly better 10-year progression-free survival compared with patients in the CHOP-rituximab arm (56% v 42%; P=0.01), but 10-year overall survival was not different between the two arms (75% v 81%; P=0.13) (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - January 25, 2018 Category: Consumer Health News Source Type: news

Pfizer announces positive top-line results for potential biosimilar to Rituxan ® / MabThera®
Pfizer Inc. has announced that REFLECTIONS B3281006, a comparative safety and efficacy study of PF-05280586 versus MabThera® (rituximab-EU), met its primary endpoint. PF-05280586 is being developed by Pfizer as a potential biosimilar to Rituxan® (rituximab-US) / MabThera® (1). The trial demonstrated equivalence in overall response rate (ORR) for the first-line treatment of patients with CD20-positive, low tumor burden, follicular lymphoma. (Source: World Pharma News)
Source: World Pharma News - January 25, 2018 Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news

Rituximab Outperforms Other Drugs in RRMS Rituximab Outperforms Other Drugs in RRMS
In a new study, rituximab was superior to other drugs -- including fingolimod, natalizumab, and dimethyl fumarate -- in efficacy, safety, and tolerability in patients with relapsing-remitting MS.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 11, 2018 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news

First-Line Rituximab Bests Other MS Drugs in Sweden (CME/CE)
(MedPage Today) -- Superior drug survival, better efficacy over injectables, oral drugs (Source: MedPage Today Neurology)
Source: MedPage Today Neurology - January 9, 2018 Category: Neurology Source Type: news

Rituximab Maintenance a'Relevant' Option in Elderly CLL Patients Rituximab Maintenance a'Relevant' Option in Elderly CLL Patients
Two-years of rituximab maintenance therapy can prolong remission in selected elderly patients with chronic lymphocytic leukemia (CLL) in first remission after an abbreviated front-line course of fludarabine, cyclophosphamide and rituximab (FCR), according to a study from France.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 4, 2018 Category: Consumer Health News Tags: Medscape Today News Source Type: news

Rituximab Effective for Lupus - Associated Cytopenia
Overall initial response rate of 86 percent in 71 patients, with complete response for 60.5 percent (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - December 27, 2017 Category: Cancer & Oncology Tags: Cardiology, Dermatology, Nephrology, Neurology, Oncology, Pharmacy, Pulmonology, Rheumatology, Journal, Source Type: news

Targeted Drug Beats Chemo in CLL Combo Therapy (CME/CE)
(MedPage Today) -- Venetoclax plus rituximab boosts survival over chemo combo (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - December 12, 2017 Category: Hematology Source Type: news

Venetoclax and Rituximab: New Standard of Care in CLL? Venetoclax and Rituximab: New Standard of Care in CLL?
The new combination of venetoclax and rituximab was superior to the standard-of-care combination of bendamustine and rituximab in the treatment of relapsed/refractory CLL.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 12, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Roche announces phase III data showing Venclexta/Venclyxto plus MabThera/Rituxan reduced the risk of disease progression or death by 83% compared to a standard of care regimen in previously treated chronic lymphocytic leukaemia
Roche today announced the first results from the pivotal phase III MURANO study evaluating Venclexta ™/Venclyxto™ (venetoclax) plus MabThera®/Rituxan® (rituximab) compared to bendamustine plus MabThera®/Rituxan® (BR) for the treatment of people with relapsed or refractory chronic lymphocytic leukaemia (CLL). The results showed that a fixed duration of treatment with Venclexta/Venclyxto plus MabThera/Rituxan significantly reduced the risk of disease progression or death (progression-free survival; PFS, as assessed by investigator) by 83% compared with BR (HR=0.17; 95% CI 0.11-0.25; p (Source: Roche Media News)
Source: Roche Media News - December 12, 2017 Category: Pharmaceuticals Source Type: news

Roche announces phase III data showing Venclexta/Venclyxto plus MabThera/Rituxan reduced the risk of disease progression or death by 83% compared to a standard of care regimen in previously treated chronic lymphocytic leukaemia
Roche today announced the first results from the pivotal phase III MURANO study evaluating Venclexta ™/Venclyxto™ (venetoclax) plus MabThera®/Rituxan® (rituximab) compared to bendamustine plus MabThera®/Rituxan® (BR) for the treatment of people with relapsed or refractory chronic lymphocytic leukaemia (CLL). The results showed that a fixed duration of treatment with Venclexta/Venclyxto plus MabThera/Rituxan significantly reduced the risk of disease progression or death (progression-free survival; PFS, as assessed by investigator) by 83% compared with BR (HR=0.17; 95% CI 0.11-0.25; p (Source: Roche Investor Update)
Source: Roche Investor Update - December 12, 2017 Category: Pharmaceuticals Source Type: news

Phase II data showed Roche ’s investigational polatuzumab vedotin plus bendamustine and MabThera/Rituxan (BR) increased complete response rates compared to BR alone in previously treated aggressive lymphoma
Roche today announced positive results from the randomised phase II GO29365 study that compared polatuzumab vedotin in combination with bendamustine plus MabThera ®/Rituxan® (rituximab) (BR) against BR alone in people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not candidates for haematopoietic stem cell transplant. (Source: Roche Media News)
Source: Roche Media News - December 10, 2017 Category: Pharmaceuticals Source Type: news

Phase II data showed Roche ’s investigational polatuzumab vedotin plus bendamustine and MabThera/Rituxan (BR) increased complete response rates compared to BR alone in previously treated aggressive lymphoma
Roche today announced positive results from the randomised phase II GO29365 study that compared polatuzumab vedotin in combination with bendamustine plus MabThera ®/Rituxan® (rituximab) (BR) against BR alone in people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not candidates for haematopoietic stem cell transplant. (Source: Roche Investor Update)
Source: Roche Investor Update - December 10, 2017 Category: Pharmaceuticals Source Type: news

Phase 3 Study Evaluating IMBRUVICA ® (ibrutinib) in Combination with Rituximab in Waldenström’s Macroglobulinemia Met Primary Endpoint
(Source: Johnson and Johnson)
Source: Johnson and Johnson - December 5, 2017 Category: Pharmaceuticals Source Type: news

Roche, AbbVie leukemia drug superior to older medicine in study
(Reuters) - Patients with a type of leukemia that had relapsed who received the new drug Venclexta in combination with Rituxan went significantly longer without the disease worsening than those treated with Rituxan and Treanda, according to interim results from a pivotal late stage study released on Tuesday. (Source: Reuters: Health)
Source: Reuters: Health - November 21, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

FDA approves Roche ’s Gazyva for previously untreated advanced follicular lymphoma
Roche announced today that the US Food and Drug Administration (FDA) approved Gazyva ® (obinutuzumab) in combination with chemotherapy, followed by Gazyva alone in those who responded, for people with previously untreated advanced follicular lymphoma (stage II bulky, III or IV). The approval is based on results from the phase III GALLIUM study, which showed superior progression-fre e survival (PFS) for patients who received this Gazyva-based regimen compared with those who received a Rituxan® (rituximab)-based regimen as an initial (first-line) therapy. Follicular lymphoma, the most common slow-growing (indolent) f...
Source: Roche Media News - November 17, 2017 Category: Pharmaceuticals Source Type: news

FDA approves Roche ’s Gazyva for previously untreated advanced follicular lymphoma
Roche announced today that the US Food and Drug Administration (FDA) approved Gazyva ® (obinutuzumab) in combination with chemotherapy, followed by Gazyva alone in those who responded, for people with previously untreated advanced follicular lymphoma (stage II bulky, III or IV). The approval is based on results from the phase III GALLIUM study, which showed superior progression-fre e survival (PFS) for patients who received this Gazyva-based regimen compared with those who received a Rituxan® (rituximab)-based regimen as an initial (first-line) therapy. Follicular lymphoma, the most common slow-growing (indolent) f...
Source: Roche Investor Update - November 17, 2017 Category: Pharmaceuticals Source Type: news